Immunotherapy targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, has also been demonstrated to be one of the most hopeful cancer treatments, with positive results in KRAS mutated cancers, as further described in [38,60]. The gene discussed is CTLA4; the disease is cancer.